top of page

Galleri Cancer Blood Test

Writer: Dr. Garg
Dr. Garg
Oct 28
1 min read

A blood test that can screen for more than 50 cancers just moved one step closer to FDA approval. On September 23rd, 2026, an FDA advisory committee voted 7–2 that the benefits of GRAIL’s Galleri multi-cancer early detection test outweigh its risks for adults age 50 and older.


Galleri looks for cancer-associated methylation patterns in cell-free DNA from a single blood draw and may detect cancers for which we currently have no routine screening test. But there are important limitations: in the large study reviewed by the FDA, Galleri detected only about one-third of cancers diagnosed during the following year (sensitivity 33%), meaning a negative result absolutely does not rule out cancer.


But Galleri has a low false positive rate of 0.5%. If there is a positive Galleri test, there is a high likelihood of cancer.


We also don't know if the Galleri screening reduces cancer deaths, and it should never replace established screening such as mammograms, colonoscopies, lung cancer screening, cervical cancer screening, prostate cancer screening. The FDA has not approved Galleri yet. The agency will make the final decision.


This technology is exciting, but we're not yet at the point where one blood test can reliably tell you that you're cancer-free!





Recent Posts

See All

Comments


bottom of page